Aurinia Pharmaceuticals Inc. has announced a significant management transition, effective March 23, 2026. Kevin Tang, who has served as the Chair of the Board since 2024, has been appointed as the new Chief Executive Officer (CEO) of the company, succeeding Peter Greenleaf. Greenleaf, who has been with Aurinia for seven years, will continue to assist the company as a consultant during the transition period. This change comes at a pivotal time for Aurinia, as its lead product, LUPKYNIS, is gaining traction as a standard therapy for lupus nephritis, and the company is advancing its pipeline product, aritinercept, through clinical studies.

In addition to Tang's appointment, Aurinia has also appointed Ryan Cole as Chief Operating Officer and Michael Hearne as Chief Financial Officer. Cole has been with Tang Capital Management since 2014 and has experience in various operational roles, while Hearne brings extensive financial expertise from his previous roles in other biopharmaceutical companies. The company has also created the position of Lead Independent Director, appointing Craig Johnson to this role, effective March 21, 2026. This restructuring is expected to enhance governance and operational execution as Aurinia continues to focus on delivering innovative therapies for autoimmune diseases.

The management transition reflects Aurinia's commitment to strengthening its leadership team and positioning itself for future growth. The company is optimistic about its strategic outlook, particularly with the ongoing development of its product pipeline and the potential for significant market impact. The leadership changes are anticipated to have a noticeable positive effect on the company's stock price as investors respond to the new direction and leadership capabilities.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.